Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)

BACKGROUND: Immunotherapy has revolutionized the treatment of cancer. However, microsatellite stable (MSS) metastatic colorectal cancer (mCRC) shows a low response to PD-1 inhibitors. Antiangiogenic therapy can enhance anti-PD-1 efficacy, but it still cannot meet clinical needs. Increasing evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Wensi, Lei, Jun, Ke, Shaobo, Chen, Yuan, Xiao, Jiping, Tang, Ze, Wang, Li, Ren, Yiping, Alnaggar, Mohammed, Qiu, Hu, Shi, Wei, Yin, Lei, Chen, Yongshun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679864/
https://www.ncbi.nlm.nih.gov/pubmed/38024475
http://dx.doi.org/10.1016/j.eclinm.2023.102315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679864/
https://www.ncbi.nlm.nih.gov/pubmed/38024475
http://dx.doi.org/10.1016/j.eclinm.2023.102315

Ejemplares similares